HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$28.26
Day range
$28.30 - $29.26
Year range
$23.42 - $62.58
Market cap
1.69B USD
Avg Volume
607.13K
P/E ratio
2.59
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 8.73M | 6.56% |
Operating expense | 41.53M | 33.90% |
Net income | -89.29M | -9.49% |
Net profit margin | -1.02K | -2.75% |
Earnings per share | -1.55 | -6.90% |
EBITDA | -105.35M | -16.12% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 893.38M | 49.40% |
Total assets | 1.56B | 83.06% |
Total liabilities | 88.99M | -15.88% |
Total equity | 1.47B | — |
Shares outstanding | 57.92M | — |
Price to book | 1.12 | — |
Return on assets | -16.56% | — |
Return on capital | -17.10% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -89.29M | -9.49% |
Cash from operations | -111.49M | -11.64% |
Cash from investing | 112.59M | -9.61% |
Cash from financing | 1.62M | -72.39% |
Net change in cash | 2.72M | -91.11% |
Free cash flow | -87.33M | -20.46% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
487
